Kite Pharma partners with Leiden University Medical Center on T cell receptors

13 January 2016

US cancer drug developer Kite Pharma’s (Nasdaq: KITE) European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection.

Kite’s shares advanced 4.8% to $54.71 ahead of the announcement, but dipped 1.2% to $53.80 in mid-morning trading today.

Under the terms of the agreement, Kite Pharma EU will partner with the LUMC Department of Clinical Oncology and Professor Dr Sjoerd van der Burg, a leader in the research of HPV-associated cancers. Kite will also receive an exclusive option to license multiple TCR gene sequences for the development and commercialization of product candidates. Financial details of the deal were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK